Global Anti-VEGF/VEGFR Monoclonal Antibodies Market Growth (Status and Outlook) 2024-2030

Global Anti-VEGF/VEGFR Monoclonal Antibodies Market Growth (Status and Outlook) 2024-2030

Anti-VEGF/VEGFR monoclonal antibodies are targeted therapeutic agents designed to inhibit the activity of vascular endothelial growth factor (VEGF) and its receptor (VEGFR). These antibodies work by blocking the signaling pathways that promote angiogenesis, the formation of new blood vessels, which is a critical process in the growth and spread of tumors. By preventing the development of the blood supply needed for tumor survival and growth, these drugs are used in the treatment of various cancers, including colorectal, lung, and kidney cancers. Anti-VEGF/VEGFR therapies have shown efficacy in slowing disease progression and improving patient outcomes.

The global Anti-VEGF/VEGFR Monoclonal Antibodies market size is projected to grow from US$ 565 million in 2024 to US$ 822 million in 2030; it is expected to grow at a CAGR of 6.4% from 2024 to 2030.

LPI (LP Information)' newest research report, the “Anti-VEGF/VEGFR Monoclonal Antibodies Industry Forecast” looks at past sales and reviews total world Anti-VEGF/VEGFR Monoclonal Antibodies sales in 2022, providing a comprehensive analysis by region and market sector of projected Anti-VEGF/VEGFR Monoclonal Antibodies sales for 2023 through 2029. With Anti-VEGF/VEGFR Monoclonal Antibodies sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti-VEGF/VEGFR Monoclonal Antibodies industry.

This Insight Report provides a comprehensive analysis of the global Anti-VEGF/VEGFR Monoclonal Antibodies landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Anti-VEGF/VEGFR Monoclonal Antibodies portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Anti-VEGF/VEGFR Monoclonal Antibodies market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-VEGF/VEGFR Monoclonal Antibodies and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-VEGF/VEGFR Monoclonal Antibodies.

United States market for Anti-VEGF/VEGFR Monoclonal Antibodies is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Anti-VEGF/VEGFR Monoclonal Antibodies is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Anti-VEGF/VEGFR Monoclonal Antibodies is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Anti-VEGF/VEGFR Monoclonal Antibodies players cover Roche, Eli Lilly, Pfizer, Regeneron Pharmaceuticals, Novartis, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Anti-VEGF/VEGFR Monoclonal Antibodies market by product type, application, key players and key regions and countries.

Segmentation by Type:
Bevacizumab
Ramucirumab
Ranibizumab

Segmentation by Application:
Hospitals
Clinics

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
Bevacizumab
Ramucirumab
Ranibizumab

Segmentation by Application:
Hospitals
Clinics

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Roche
Eli Lilly
Pfizer
Regeneron Pharmaceuticals
Novartis
Alphamab Oncology

Please note: The report will take approximately 2 business days to prepare and deliver.